Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.

Teclistamab significantly improves progression-free and overall survival in relapsed or refractory multiple myeloma patients with 1-3 prior therapies, achieving 69.8% 18-month progression-free survival.

• Why it matters: Multiple myeloma remains difficult to treat after initial therapies, and effective early-line options are limited. Understanding teclistamab's efficacy could expand treatment options for these patients.
• What they did: A randomized trial involving 593 patients compared teclistamab to standard regimens (PVd or Kd), assessing progression-free survival, response rates, and safety over a median follow-up of 17.3 months.
• The result: Teclistamab outperformed standard therapies, with higher response rates and survival benefits, though it was associated with frequent grade 3 or 4 infections and manageable adverse events.